Pricing and Access Archives

Market Access Trends 2026

How Four Pillars Are Shaping Latin America and MENA Market Access

March 25, 2026

Latin American and MENA markets have long faced the challenge of balancing constrained public budgets with rising demand for newer therapies. In 2025, governments in these regions took concrete steps to modernize pricing rules, raise evidence expectations, expand partnership models, and...

Market Access Trends 2026

How Regulatory–HTA Convergence Is Reshaping European Market Access

March 24, 2026

Across Europe, 2025 accelerated a shift from sequential regulatory and access steps to more connected process through the Joint Clinical Assessment. Regulatory approvals, and clinical portion of HTA evaluation are now more tightly linked, which has the potential to bring the...

Market Access Trends 2026

How MFN and Direct-to-Consumer Models Are Rewiring US Market Access

March 23, 2026

Globally, 2025 marked a shift from debating drug pricing policy to implementing it. Pricing pressure intensified, evidence expectations rose, and long-standing access models began to change amid political and fiscal realities. In Trinity’s webinar “Around the World in Market Access 2026:...

Blog

A Shrinking Safety Net: OBBBA’s Ripple Effects on the Pharma Industry

August 26, 2025

President Trump signed the “One Big Beautiful Bill Act” (OBBBA) into law on July 4, 2025. The OBBBA is projected to reduce federal health spending by an estimated $900 billion[1] over the next decade. Central to the legislation is the estimated...

Blog

Joint Clinical Assessment in the EU: What Life Sciences Companies Need to Know

June 13, 2025

March 2025 marked a pivotal moment for pharmaceutical and biotech companies operating in the European Union (EU) as the first two molecules began to proceed through the Joint Clinical Assessment (JCA) process. At a recent seminar hosted by Trinity Life Sciences,...

Blog

Pricing and Access in Germany: Innovation and Strong Evidence Rewarded

June 9, 2025

Germany’s Medical Research Act (Medizinforschungsgesetz or MFG), which came into force on October 30, 2024, is a major legislative reform aimed at strengthening Germany’s position as an attractive environment for medical innovation and pharmaceutical development. The act provides for confidential negotiated...

Blog

Seizing the Storm: Why Pharma Must Plan, Not Panic in Trump’s Second Term

April 29, 2025

The first 100 days of President Trump’s return to the White House have been anything but ordinary. With a true “Flood the Zone” strategy, there has been a flurry of executive orders, leadership reshuffles, and a re-assertion of executive power, which...

Blog

Learnings to Kick-Start 2025: Health Equity

January 28, 2025

Health equity continues to be a hot topic in the life sciences industry. ISPOR EU sessions addressed several key questions surrounding the impact of health equity on HTA decision-making, the methodologies that should be employed, and the opportunities and challenges of...

Blog

Maximum Fair Price Round 2: Passing the Baton

January 24, 2025

On January 20, 2025, the Centers for Medicare & Medicaid Services (CMS) announced the set of fifteen drugs targeted for the second round of Maximum Fair Price (MFP) “negotiations” under the Inflation Reduction Act (IRA). With the outcomes of the first...